CN109311820A - 2,6-二甲基嘧啶酮衍生物的盐及其用途 - Google Patents

2,6-二甲基嘧啶酮衍生物的盐及其用途 Download PDF

Info

Publication number
CN109311820A
CN109311820A CN201780029840.2A CN201780029840A CN109311820A CN 109311820 A CN109311820 A CN 109311820A CN 201780029840 A CN201780029840 A CN 201780029840A CN 109311820 A CN109311820 A CN 109311820A
Authority
CN
China
Prior art keywords
crystal form
salt
acid
addition salts
benzene sulfonate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780029840.2A
Other languages
English (en)
Other versions
CN109311820B (zh
Inventor
林润锋
陈亮
王晓军
张英俊
张健存
曹生田
康宁
聂飚
许娟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangdong HEC Pharmaceutical
Original Assignee
Sunshine Lake Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Lake Pharma Co Ltd filed Critical Sunshine Lake Pharma Co Ltd
Publication of CN109311820A publication Critical patent/CN109311820A/zh
Application granted granted Critical
Publication of CN109311820B publication Critical patent/CN109311820B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Surgery (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

本发明涉及2,6‑二甲基嘧啶酮衍生物的盐及其用途。本发明还涉及包含所述盐或它们的组合的药物组合物，以及所述盐或所述药物组合物在制备用于治疗和预防组织或器官纤维化疾病的药物中的用途。

Description

PCT国内申请，说明书已公开。

Claims (44)

  1. PCT国内申请，权利要求书已公开。
CN201780029840.2A 2016-07-27 2017-07-26 2,6-二甲基嘧啶酮衍生物的盐及其用途 Active CN109311820B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610601939 2016-07-27
CN2016106019392 2016-07-27
PCT/CN2017/094409 WO2018019244A1 (zh) 2016-07-27 2017-07-26 2,6-二甲基嘧啶酮衍生物的盐及其用途

Publications (2)

Publication Number Publication Date
CN109311820A true CN109311820A (zh) 2019-02-05
CN109311820B CN109311820B (zh) 2022-09-27

Family

ID=61015810

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780029840.2A Active CN109311820B (zh) 2016-07-27 2017-07-26 2,6-二甲基嘧啶酮衍生物的盐及其用途

Country Status (2)

Country Link
CN (1) CN109311820B (zh)
WO (1) WO2018019244A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7393325B2 (ja) 2017-07-14 2023-12-06 サンシャイン・レイク・ファーマ・カンパニー・リミテッド ピリミドン化合物を調製するための方法
WO2020078445A1 (zh) * 2018-10-19 2020-04-23 广东东阳光药业有限公司 一种治疗纤维化疾病的药物组合或药物组合物
WO2023056935A1 (zh) * 2021-10-09 2023-04-13 广东东阳光药业有限公司 抗纤维化组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103492370A (zh) * 2011-04-22 2014-01-01 西格诺药品有限公司 取代的二氨基甲酰胺和二氨基甲腈嘧啶，其组合物，和用其治疗的方法
CN103570630A (zh) * 2012-07-18 2014-02-12 广东东阳光药业有限公司 氮杂环衍生物及其在药物中的应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103492370A (zh) * 2011-04-22 2014-01-01 西格诺药品有限公司 取代的二氨基甲酰胺和二氨基甲腈嘧啶，其组合物，和用其治疗的方法
CN103570630A (zh) * 2012-07-18 2014-02-12 广东东阳光药业有限公司 氮杂环衍生物及其在药物中的应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
尼尔•G•安德森: "《实用有机合成工艺研发手册》", 31 January 2011, 科学出版社 *
张昌军 等: "《有机化学实验》", 31 August 2006, 中国医药科技出版社 *

Also Published As

Publication number Publication date
CN109311820B (zh) 2022-09-27
WO2018019244A1 (zh) 2018-02-01

Similar Documents

Publication Publication Date Title
US8227463B2 (en) Amorphous body composed of heterocyclic compound, solid dispersion and pharmaceutical preparation each comprising the same, and process for production of the same
CN103553966B (zh) 选择性雄激素受体调节剂的固体形态
TWI718104B (zh) AHU-377結晶型游離酸、半鈣鹽、α-苯乙胺鹽及其製備方法和應用
CN107663177A (zh) 2,6‑二甲基嘧啶酮衍生物的盐及其用途
CN105121409B (zh) 德罗格韦钠盐的晶型及其制备方法
WO2018103726A1 (zh) 一种溴结构域蛋白抑制剂药物的晶型及其制备方法和用途
WO2021104427A1 (zh) 含氮三环化合物的晶型及其用途
CN109311820A (zh) 2,6-二甲基嘧啶酮衍生物的盐及其用途
WO2021104421A1 (zh) 含氮三环化合物的无定形及其用途
CN105085542B (zh) 噁唑烷酮类化合物的晶型和无定形
WO2015176591A1 (zh) 贝曲西班盐及其制备方法和用途
WO2019218883A1 (zh) 一种二氢嘧啶类化合物的固体形式及其制备方法和用途
TW201920160A (zh) ２－（５－（４－（２－嗎啉乙氧基）苯基）吡啶－２－基）－ｎ－芐乙醯胺之固態形式
CN111825547B (zh) 一种芳基丙酸类化合物的盐及其制药用途
WO2023193563A1 (zh) 一种噻吩并吡啶化合物的晶型a、制备方法及其药物组合物
CN107400125A (zh) 二氢嘧啶衍生物的晶型、盐和复合物及其在药物中的应用
TWI668222B (zh) 5型磷酸二酯酶抑制劑的甲磺酸鹽多晶物及其製備方法和應用
WO2022166638A1 (zh) 吲哚衍生物的盐及其用途
CN105085421B (zh) 奥比特嗪‑富马酸盐、水合物、晶型及其制备方法
WO2023061468A1 (zh) 含氮三环化合物的新晶型及其用途
WO2018130226A1 (zh) 利奥西呱的新晶型及其制备方法和用途
KR20060116422A (ko) 용해도가 개선된 실로스타졸 복합체 조성물 및 그 제조방법
CN114989136A (zh) 吲哚衍生物的盐及其用途
CN114835678A (zh) 吲哚衍生物的盐及其用途
CN118221649A (zh) 氟取代的吲唑化合物的晶型及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address

Address after: 523808 No.1, Gongye North Road, Songshanhu Park, Dongguan City, Guangdong Province

Patentee after: Guangdong Dongyangguang Pharmaceutical Co.,Ltd.

Address before: 523808 No. 1 Industrial North Road, Songshan Industrial Park, Songshan, Guangdong, Dongguan, Hubei

Patentee before: SUNSHINE LAKE PHARMA Co.,Ltd.

CP03 Change of name, title or address